Want to see JP:4894 full AI Analyst Report?
Cuorips Inc. (4894) AI Stock Analysis
Cuorips Inc.
(TSE/TYO:4894)
The score is held back primarily by weak financial performance—declining revenue, widening losses, and rising cash burn—despite a notably strong balance sheet with zero debt. Technicals are supportive with the stock trading above key moving averages and moderate positive momentum, while valuation remains challenged due to negative earnings and no dividend yield data.
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 62.68B
- Dividend Yield
- ―
- Average Volume (3M)
- 139.25K
- Price to Earnings (P/E)
- -51.0
- Beta (1Y)
- 0.98
- Revenue Growth
- -50.60%
- EPS Growth
- -70.48%
- Country
- Japan
- Employees
- 51
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Cuorips Inc. Business Overview & Revenue Model
Company Description
Cuorips Inc. specializes in the comprehensive lifecycle of iPS cell-derived cardiomyocyte sheets, undertaking their research, development, production, commercialization, and distribution. The firm's portfolio extends to include cellular, tissue-based...
Cuorips Inc. Financial Statement Overview
Summary
Balance sheet strength (zero debt and sizable equity) supports financial stability, but operating performance is very weak: revenue declined year over year, losses widened materially, margins deteriorated, and cash burn increased with consistently negative operating and free cash flow.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
24Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 128.59M | 212.33M | 175.21M | 23.10M | 38.28M | 13.91M |
| Gross Profit | 5.13M | 45.90M | 91.56M | -60.47M | -57.64M | -82.09M |
| EBITDA | -1.12B | -996.81M | -513.57M | -518.38M | -371.78M | -280.46M |
| Net Income | -1.14B | -1.02B | -644.34M | -632.18M | -452.08M | -375.34M |
Balance Sheet | ||||||
| Total Assets | 4.81B | 5.12B | 5.74B | 6.18B | 3.59B | 4.04B |
| Cash, Cash Equivalents and Short-Term Investments | 3.32B | 3.90B | 4.79B | 5.58B | 2.94B | 3.34B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 354.46M | 353.83M | 211.91M | 200.96M | 133.79M | 149.36M |
| Stockholders Equity | 4.44B | 4.75B | 5.53B | 5.98B | 3.45B | 3.90B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.10B | -892.81M | -474.83M | -412.18M | -249.45M |
| Operating Cash Flow | 0 | -1.06B | -812.62M | -451.06M | -401.61M | -220.76M |
| Investing Cash Flow | 0 | -7.59M | -117.99M | -33.50M | -8.97M | -28.44M |
| Financing Cash Flow | 0 | 176.84M | 143.11M | 3.12B | 10.69M | 48.54M |
Cuorips Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 7060.00 is above the 20-day moving average (MA) of 6528.50, above the 50-day MA of 5963.80, and above the 200-day MA of 6166.02, indicating a bullish trend. The MACD of 332.85 indicates Negative momentum. The RSI at 60.33 is Neutral, neither overbought nor oversold. The STOCH value of 84.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.
Cuorips Inc. Peers Comparison
Overall Rating
- JP:489454Neutral
JP:459348Neutral
JP:497842Neutral
JP:777442Neutral
JP:459940Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4894 | 54Neutral | JPY 62.70B | -51.03 | ― | ― | -50.60% | -70.48% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 40Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4894 | Cuorips Inc. | 7060.00 | 370.00 | 5.53% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026